Detalhe da pesquisa
1.
A practical guide to the appropriate analysis of eGFR data over time: A simulation study.
Pharm Stat
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568372
2.
Conditional power and information fraction calculations at an interim analysis for random coefficient models.
Pharm Stat
; 23(2): 276-283, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919258
3.
Theory of Mind and Social Informant Discrepancy in Autism.
Child Psychiatry Hum Dev
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502300
4.
Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria.
Nephrol Dial Transplant
; 36(12): 2208-2215, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367720
5.
Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing.
AAPS PharmSciTech
; 22(7): 224, 2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34410534
6.
Performance of Multiple-Batch Approaches to Pharmacokinetic Bioequivalence Testing for Orally Inhaled Drug Products with Batch-to-Batch Variability.
AAPS PharmSciTech
; 22(7): 225, 2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34410557
7.
Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
J Biopharm Stat
; 30(4): 593-606, 2020 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31829826
8.
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study.
Pharm Stat
; 16(4): 250-266, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28470952
9.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(7): 789-96, 2016 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27599039
10.
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
Am J Kidney Dis
; 68(3): 392-401, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27032886
11.
Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
J Biopharm Stat
; 23(5): 1188-200, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23957523
12.
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.
Clin Kidney J
; 15(1): 136-144, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35035944
13.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(9): e16, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27727233
14.
Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials.
J Allergy Clin Immunol
; 125(2): 390-396.e8, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20159250
15.
Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?
Pharm Stat
; 8(4): 333-45, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19180520
16.
The epidemiology of Shiga toxin-producing Escherichia coli infections in the South East of England: November 2013-March 2017 and significance for clinical and public health.
J Med Microbiol
; 68(6): 930-939, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30994441
17.
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
J Nephrol
; 32(5): 811-821, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401795
18.
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
J Clin Oncol
; 23(25): 6139-48, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16135480
19.
Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?
Clin Pharmacol Ther
; 105(2): 326-328, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30652313
20.
Analysis of duration of response in oncology trials.
Contemp Clin Trials
; 29(4): 456-65, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18187370